ELR510444Novel microtubule disruptor CAS# 1233948-35-0 |
- Gatifloxacin
Catalog No.:BCC1064
CAS No.:112811-59-3
- Dexrazoxane HCl (ICRF-187, ADR-529)
Catalog No.:BCC1087
CAS No.:149003-01-0
- Doxorubicin (Adriamycin) HCl
Catalog No.:BCC1117
CAS No.:25316-40-9
- Etoposide
Catalog No.:BCC1151
CAS No.:33419-42-0
- Genistein
Catalog No.:BCN5499
CAS No.:446-72-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1233948-35-0 | SDF | Download SDF |
PubChem ID | 46847888 | Appearance | Powder |
Formula | C19H16N2O2S2 | M.Wt | 368.47 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 37 mg/mL (100.42 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | N-[5-(5-cyanothiophen-2-yl)-2-methylphenyl]-4-methylbenzenesulfonamide | ||
SMILES | CC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=CC(=C2)C3=CC=C(S3)C#N)C | ||
Standard InChIKey | GRYXROIHHXHFND-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C19H16N2O2S2/c1-13-3-8-17(9-4-13)25(22,23)21-18-11-15(6-5-14(18)2)19-10-7-16(12-20)24-19/h3-11,21H,1-2H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | ELR510444 is a novel microtubule disruptor; inhibits MDA-MB-231 cell proliferation with IC50 of 30.9 nM; not a substrate for the P-glycoprotein drug transporter and retains activity in βIII-tubulin-overexpressing cell lines.
IC50 value: 30.9 nM(MDA-MB-231 cell) [1]
Target: Microtubule disruptor
ELR510444 is not a substrate for the P-glycoprotein drug transporter and retains activity in βIII-tubulin-overexpressing cell lines, suggesting that it circumvents both clinically relevant mechanisms of drug resistance to this class of agents. ELR510444 also shows potent antitumor activity in the MDA-MB-231 xenograft model with at least a 2-fold therapeutic window. Studies in tumor endothelial cells show that a low concentration of ELR510444 (30 nM) rapidly alters endothelial cell shape, similar to the effect of the vascular disrupting agent combretastatin A4. ELR510444 is a novel microtubule-disrupting agent with potential antivascular effects and in vivo antitumor efficacy [1]. ELR510444 decreased HIF-1α and HIF-2α levels, reduced RCC cell viability and clonogenic survival, and induced apoptosis. VHL-deficient RCC cells were more sensitive to ELR510444-mediated apoptosis and restoration of VHL promoted drug resistance. Higher concentrations of ELR51044 promoted apoptosis independently of VHL status, possibly due to the microtubule destabilizing properties of this agent. ELR510444 significantly reduced tumor burden in the 786-O and A498 RCC xenograft models [2]. References: |
ELR510444 Dilution Calculator
ELR510444 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.7139 mL | 13.5696 mL | 27.1393 mL | 54.2785 mL | 67.8481 mL |
5 mM | 0.5428 mL | 2.7139 mL | 5.4279 mL | 10.8557 mL | 13.5696 mL |
10 mM | 0.2714 mL | 1.357 mL | 2.7139 mL | 5.4279 mL | 6.7848 mL |
50 mM | 0.0543 mL | 0.2714 mL | 0.5428 mL | 1.0856 mL | 1.357 mL |
100 mM | 0.0271 mL | 0.1357 mL | 0.2714 mL | 0.5428 mL | 0.6785 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Microtubules are involved in nucleic and cell organization, division of intracellular structure, and intracellular transport, as well as ciliary and flagellar motility. Microtubule-targeting agents are some of the most effective chemotherapeutic drugs used in the clinic today. ELR510444 is a novel microtubule disruptor with multiple mechanisms of action.
In vitro: ELR510444 has potent microtubuledisrupting activity, causing a loss of intracellular microtubules and the formation of aberrant mitotic spindles and leading to mitotic arrest and apoptosis of cancer cells. ELR510444 inhibited cell proliferation, inhibited the rate and extent of purified tubulin assembly potently, and displaced colchicine from tubulin, revealing that the drug directly interacts with tubulin at the colchicine-binding site [1].
In vivo: ELR510444 also shows potent antitumor activity in the MDA-MB-231 xenograft model with at least a 2-fold therapeutic window [1].
Clinical trial: Up to now, ELR510444 is still in the preclinical development stage.
Reference:
[1] Risinger AL, Westbrook CD, Encinas A, Mülbaier M, Schultes CM, Wawro S, Lewis JD, Janssen B, Giles FJ, Mooberry SL. ELR510444, a novel microtubule disruptor with multiple mechanisms of action. J Pharmacol Exp Ther. 2011 Mar;336(3):652-60.
- Methyl 4-caffeoylquinate
Catalog No.:BCN3442
CAS No.:123372-74-7
- CAY10650
Catalog No.:BCC4178
CAS No.:1233706-88-1
- kb NB 142-70
Catalog No.:BCC1675
CAS No.:1233533-04-4
- Dipsacobioside
Catalog No.:BCN6552
CAS No.:123350-57-2
- AZ20
Catalog No.:BCC1389
CAS No.:1233339-22-4
- Clofarabine
Catalog No.:BCC1078
CAS No.:123318-82-1
- 2'-O-Methylhelichrysetin
Catalog No.:BCN4792
CAS No.:123316-64-3
- 6alpha-Hydroxytomentosin
Catalog No.:BCN7303
CAS No.:1232676-22-0
- VE-821
Catalog No.:BCC1207
CAS No.:1232410-49-9
- LY2835219
Catalog No.:BCC1113
CAS No.:1231930-82-7
- LY2835219 free base
Catalog No.:BCC1722
CAS No.:1231929-97-7
- Cefepime Dihydrochloride Monohydrate
Catalog No.:BCC5261
CAS No.:123171-59-5
- Z-Arg-OH
Catalog No.:BCC3060
CAS No.:1234-35-1
- LY2606368
Catalog No.:BCC4105
CAS No.:1234015-52-1
- Boc-Glu(Ofm)-OH
Catalog No.:BCC3391
CAS No.:123417-18-5
- Rivastigmine
Catalog No.:BCC1900
CAS No.:123441-03-2
- XMD8-92
Catalog No.:BCC2062
CAS No.:1234480-50-2
- LRRK2-IN-1
Catalog No.:BCC1706
CAS No.:1234480-84-2
- PM 102
Catalog No.:BCC6105
CAS No.:1234564-95-4
- PNU 282987
Catalog No.:BCC7318
CAS No.:123464-89-1
- LY2608204
Catalog No.:BCC4969
CAS No.:1234703-40-2
- SAR191801
Catalog No.:BCC6393
CAS No.:1234708-04-3
- 3-O-Caffeoylquinic acid methyl ester
Catalog No.:BCN3484
CAS No.:123483-19-2
- Demethylmurrayanine
Catalog No.:BCN4721
CAS No.:123497-84-7
ELR510444, a novel microtubule disruptor with multiple mechanisms of action.[Pubmed:21148249]
J Pharmacol Exp Ther. 2011 Mar;336(3):652-60.
Although several microtubule-targeting drugs are in clinical use, there remains a need to identify novel agents that can overcome the limitations of current therapies, including acquired and innate drug resistance and undesired side effects. In this study, we show that ELR510444 has potent microtubule-disrupting activity, causing a loss of cellular microtubules and the formation of aberrant mitotic spindles and leading to mitotic arrest and apoptosis of cancer cells. ELR510444 potently inhibited cell proliferation with an IC(50) value of 30.9 nM in MDA-MB-231 cells, inhibited the rate and extent of purified tubulin assembly, and displaced colchicine from tubulin, indicating that the drug directly interacts with tubulin at the colchicine-binding site. ELR510444 is not a substrate for the P-glycoprotein drug transporter and retains activity in betaIII-tubulin-overexpressing cell lines, suggesting that it circumvents both clinically relevant mechanisms of drug resistance to this class of agents. Our data show a close correlation between the concentration of ELR510444 required for inhibition of cellular proliferation and that required to cause significant loss of cellular microtubule density, consistent with its activity as a microtubule depolymerizer. ELR510444 also shows potent antitumor activity in the MDA-MB-231 xenograft model with at least a 2-fold therapeutic window. Studies in tumor endothelial cells show that a low concentration of ELR510444 (30 nM) rapidly alters endothelial cell shape, similar to the effect of the vascular disrupting agent combretastatin A4. These results suggest that ELR510444 is a novel microtubule-disrupting agent with potential antivascular effects and in vivo antitumor efficacy.
ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.[Pubmed:22295124]
PLoS One. 2012;7(1):e31120.
BACKGROUND: Hypoxia-inducible factor (HIF) is an attractive therapeutic target for renal cell carcinoma (RCC) as its high expression due to the loss of von Hippel-Lindau (VHL) promotes RCC progression. Considering this, we hypothesized that ELR510444, a novel orally available small molecule inhibitor of HIF activity, would reduce angiogenesis and possess significant activity in RCC. The mechanism of action and therapeutic efficacy of ELR510444 were investigated in in vitro and in vivo models of RCC. PRINCIPAL FINDINGS: ELR510444 decreased HIF-1alpha and HIF-2alpha levels, reduced RCC cell viability and clonogenic survival, and induced apoptosis. VHL-deficient RCC cells were more sensitive to ELR510444-mediated apoptosis and restoration of VHL promoted drug resistance. Higher concentrations of ELR51044 promoted apoptosis independently of VHL status, possibly due to the microtubule destabilizing properties of this agent. ELR510444 significantly reduced tumor burden in the 786-O and A498 RCC xenograft models. These effects were associated with increased necrosis and apoptosis and inhibition of angiogenesis. CONCLUSIONS: ELR510444 is a promising new HIF inhibitor that reduced RCC cell viability, induced apoptosis, and diminished tumor burden in RCC xenograft models. ELR510444 also destabilized microtubules suggesting that it possesses vascular disrupting and anti-angiogenic properties. Further investigation of ELR510444 for the therapy of RCC is warranted.